Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Farmers Insurance
Merck
Express Scripts
Healthtrust
Daiichi Sankyo

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,105,323

« Back to Dashboard

Which drugs does patent 10,105,323 protect, and when does it expire?

Patent 10,105,323 protects OFEV and is included in one NDA.

This patent has twenty-eight patent family members in twenty-four countries.

Summary for Patent: 10,105,323
Title:Pharmaceutical dosage form for immediate release of an indolinone derivative
Abstract: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate.
Inventor(s): Messerschmid; Roman (Biberach an der Riss, DE), Lach; Peter (Ulm, DE), Sokoliess; Torsten (Neu-Ulm, DE), Stopfer; Peter (Warthausen, DE), Trommeshauser; Dirk (Warthausen, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:15/590,487
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 10,105,323
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 10,105,323

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 10,105,323

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08157750Jun 6, 2008

International Family Members for US Patent 10,105,323

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072060 ➤ Sign Up
Australia 2009254556 ➤ Sign Up
Brazil PI0913235 ➤ Sign Up
Canada 2726648 ➤ Sign Up
China 102056599 ➤ Sign Up
Colombia 6280468 ➤ Sign Up
Denmark 2313087 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
AstraZeneca
Merck
Citi
Medtronic
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.